Product Code: ETC9971304 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Nephrotic Syndrome Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Nephrotic Syndrome Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Nephrotic Syndrome Market - Industry Life Cycle |
3.4 United States (US) Nephrotic Syndrome Market - Porter's Five Forces |
3.5 United States (US) Nephrotic Syndrome Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 United States (US) Nephrotic Syndrome Market Revenues & Volume Share, By Diagnosis Tests, 2021 & 2031F |
3.7 United States (US) Nephrotic Syndrome Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 United States (US) Nephrotic Syndrome Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic kidney diseases leading to a rise in nephrotic syndrome cases |
4.2.2 Advancements in diagnostic technologies and treatment options for nephrotic syndrome |
4.2.3 Growing awareness among healthcare professionals and patients about the disease and available treatment options |
4.3 Market Restraints |
4.3.1 High cost associated with the treatment and management of nephrotic syndrome |
4.3.2 Limited availability of specialized healthcare facilities for nephrotic syndrome patients |
4.3.3 Stringent regulatory requirements for the approval of new treatment options |
5 United States (US) Nephrotic Syndrome Market Trends |
6 United States (US) Nephrotic Syndrome Market, By Types |
6.1 United States (US) Nephrotic Syndrome Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Sodium Restriction Drugs, 2021- 2031F |
6.1.4 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Fluid Restriction Drugs, 2021- 2031F |
6.1.5 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Loop Diuretics, 2021- 2031F |
6.1.6 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Angiotensin-Converting Enzyme Inhibitor, 2021- 2031F |
6.1.7 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Nephrotic Syndrome Market, By Diagnosis Tests |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Urinalysis, 2021- 2031F |
6.2.3 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Glomerular Filtration Rate (GFR), 2021- 2031F |
6.2.4 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Blood Test, 2021- 2031F |
6.2.5 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Kidney Biopsy, 2021- 2031F |
6.2.6 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Computerized Tomography (CT) Scan, 2021- 2031F |
6.3 United States (US) Nephrotic Syndrome Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Clinics, 2021- 2031F |
6.3.3 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.4 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.3.5 United States (US) Nephrotic Syndrome Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Nephrotic Syndrome Market Import-Export Trade Statistics |
7.1 United States (US) Nephrotic Syndrome Market Export to Major Countries |
7.2 United States (US) Nephrotic Syndrome Market Imports from Major Countries |
8 United States (US) Nephrotic Syndrome Market Key Performance Indicators |
8.1 Average time from symptom onset to diagnosis of nephrotic syndrome |
8.2 Patient adherence to prescribed treatment regimens |
8.3 Number of clinical trials focused on nephrotic syndrome treatments |
8.4 Percentage of nephrotic syndrome patients receiving recommended regular monitoring and follow-up care |
8.5 Adoption rate of emerging therapies for nephrotic syndrome. |
9 United States (US) Nephrotic Syndrome Market - Opportunity Assessment |
9.1 United States (US) Nephrotic Syndrome Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 United States (US) Nephrotic Syndrome Market Opportunity Assessment, By Diagnosis Tests, 2021 & 2031F |
9.3 United States (US) Nephrotic Syndrome Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 United States (US) Nephrotic Syndrome Market - Competitive Landscape |
10.1 United States (US) Nephrotic Syndrome Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Nephrotic Syndrome Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |